Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
- DOI
- 10.1038/s41408-026-01524-9
- Published
- 2026 Jul 2
- Container
- Blood cancer journal
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41408-026-01524-9,
title = {Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.},
author = {Chohan KL and Saul EE and Davis RE and Hagemeister F and Steiner R and Fayad L and Ahmed S and Rodriguez A and Iyer SP and Nair R and Vega F and Chihara D and Strati P and Jain P and Malpica Castillo L and Nze C and Furqan F and Chauhan A and Hamilton MP and Henderson J and Lionel AC and Flowers CR and Neelapu S and Green MR and Westin J},
year = {2026},
journal = {Blood cancer journal},
doi = {10.1038/s41408-026-01524-9},
url = {https://doi.org/10.1038/s41408-026-01524-9}
}RIS
TY - JOUR TI - Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma. AU - Chohan KL AU - Saul EE AU - Davis RE AU - Hagemeister F AU - Steiner R AU - Fayad L AU - Ahmed S AU - Rodriguez A AU - Iyer SP AU - Nair R AU - Vega F AU - Chihara D AU - Strati P AU - Jain P AU - Malpica Castillo L AU - Nze C AU - Furqan F AU - Chauhan A AU - Hamilton MP AU - Henderson J AU - Lionel AC AU - Flowers CR AU - Neelapu S AU - Green MR AU - Westin J PY - 2026 JO - Blood cancer journal DO - 10.1038/s41408-026-01524-9 UR - https://doi.org/10.1038/s41408-026-01524-9 ER -
APA
KL, C., EE, S., RE, D., F, H., R, S., L, F., S, A., A, R., SP, I., R, N., F, V., D, C., P, S., P, J., L, M. C., C, N., F, F., A, C., MP, H., J, H., AC, L., CR, F., S, N., MR, G., & J, W. (2026). Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.. Blood cancer journal. https://doi.org/10.1038/s41408-026-01524-9
Source records
- pubmed · retrieved 2026-09-26T04:24:46.709Z